ENVVENO MEDICAL CORP (NVNO)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$11.44+3.06%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · NVNO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
NVNO — litigation filed
Dated 2026-04-29
Regulation FD Disclosure. On April 29, 2026, the Company issued a press release announcing the Company had received a favorable decision from the U.S. Food & Drug Administration in connection with the Company’s Investigational Device Exemption application for the Transcatheter Venous Valve Endoprosthesis (TAVVE ® ) pivotal study. The press release is being furnished as Exhibit 99.1 to this Current Report. Statements that are not historical fact may be considered forward-looking statements wit…
Why it matters: Monitoring cash burn is vital for understanding financial health. High burn rates could threaten operations beyond Q3 2027.
Worry ifCash burn rate reported below $3 million for Q3 2026.
Less concerning ifCash burn rate exceeds $4 million for Q3 2026.
Why it matters: Keeping cash reserves is important for running the business. Updates on cash show financial health.
Worry ifThe company announced that cash and investments are stable or growing before Q3 2026.
Less concerning ifThe company announced that cash reserves are dropping a lot before Q3 2026.
Why it matters: Updates on cash and losses will show if the company can keep running during the TAVVE study.
Worry ifThe company announced that cash reserves are going up or losses are going down.
Less concerning ifThe company announced that cash reserves are going down or losses are going up.
Why it matters: The safety results will be critical for the next stage of the TAVVE study. Positive results could lead to further patient enrollment and FDA approval.
Supportive ifThe 30-day safety results from the first cohort of 10 patients are reported as positive.
Worry ifThe safety results are bad. This raises worries about the enVVe system's future.
Why it matters: Activating clinical sites is a key step to start the pivotal study. This study could lead to the first effective treatment for severe CVI.
Supportive ifAt least 5 clinical sites are now active for the TAVVE study.
Worry ifNo clinical sites activated by the end of Q4 2026.
Why it matters: These results are critical for FDA review and could impact future enrollment and funding.
Watch forThe 30-day safety results for the first 10 patients are reported to the FDA as positive.
Also watch forThe 30-day safety results show big problems. This raises concerns about the enVVe system.
Why it matters: Keeping cash is important for running operations. It helps the company continue its studies.
Worry ifCash reserves have increased to over $28 million.
Less concerning ifCash reserves drop below $20 million by Q3 2027.
Why it matters: Keeping cash is very important. It funds operations and supports the TAVVE study.
Worry ifThe company has cash reserves over $25 million. This shows strong funding.
Less concerning ifCash reserves fall below $25 million. This raises worries about how long operations can last.
Why it matters: Starting patient enrollment is a key step for the enVVe system's development. It signals progress toward addressing a large unmet need in treating severe CVI.
Supportive ifEnrollment of the first patients in the TAVVE study begins as planned later this year.
Worry ifEnrollment does not start as expected, delaying the study timeline.
Why it matters: Keeping cash is important for running the business. Updates can show financial health.
Worry ifCash and investments stay the same or go up. This helps operations after Q3 2027.
Less concerning ifCash and investments drop a lot. This raises worries about funding operations.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$227 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $873 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,457 loss on $10,000 · 74.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.